Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by Morgan Stanley from $225.00 to $226.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 19.60% from the company’s previous close.

Several other analysts have also issued reports on JAZZ. Royal Bank Of Canada set a $194.00 price objective on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and set a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Needham & Company LLC lifted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $213.85.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $188.97 on Wednesday. The firm has a market capitalization of $11.63 billion, a P/E ratio of -31.65, a price-to-earnings-growth ratio of 1.06 and a beta of 0.26. The company has a current ratio of 1.86, a quick ratio of 1.44 and a debt-to-equity ratio of 1.00. The firm’s fifty day moving average price is $169.18 and its two-hundred day moving average price is $150.86. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the previous year, the business earned $6.51 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 4,660 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. The SEC filing for this sale provides additional information. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares in the last quarter. Capital World Investors lifted its position in shares of Jazz Pharmaceuticals by 4.4% during the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after acquiring an additional 111,735 shares during the period. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after acquiring an additional 87,576 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat: Jazz reported Q4 revenue of ~$1.20B and EPS of $6.64, topping consensus and showing year-over-year revenue growth driven by neuroscience and oncology products. JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
• Positive Sentiment: Strong oxybate/Xywav growth is a core driver of the beat and underpins management’s optimism for 2026. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: 2026 revenue outlook raised: management projects $4.25B–$4.50B for 2026 while highlighting progress on rare-disease and oncology launches — a bullish forward signal. Jazz projects 4.25B–4.50B 2026 revenue
• Positive Sentiment: Multiple analyst price-target upgrades and bullish ratings after the print (Bank of America, Wells Fargo, Morgan Stanley, RBC) lift forward sentiment and imply substantial upside from current levels. Analyst price target raises TickerReport: BofA raise
• Neutral Sentiment: Detailed context available in the earnings call transcript and investor presentation for pipeline, launch timing and margin assumptions. Investors may want to review these for items that affect long-term modeling. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Near-term pullback/volatility drivers: the stock ran up into the print (near its 52‑week high), trading volume is elevated, and some investors are likely taking profits despite the beat — a plausible reason for the intraday decline.
• Negative Sentiment: Structural/valuation considerations: Jazz still has leverage on the balance sheet and reported a negative net margin in the background data; some investors may be cautious on margins and cash flow conversion as the company invests in launches. (See earnings coverage for metrics.) Earnings Call Summary

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.